The reported incidence of immunotherapy-associated hepatitis in the literature varies according to the different agents: 2–15% in CTLA-4 inhibitors, 0–3% in PD-1 inhibitors, and 0–6% in PD-L1 inhibitors [21]. This evidence concerns the gene CTLA4 and Hepatitis.